Executive Summary
Cell MedX Corp (CMXC) reported a negative quarterly result for QQ2 2025, underscoring a precarious liquidity position despite ongoing device development. Net income stood at -$139,508 with an EPS of -$0.007, driven by operating expenses of $79,924 and a significant non-operating charge of -$139,508 (total other income/expenses net). The quarter shows no disclosed revenue, limiting visibility into top-line traction as management pursues commercialization of its eBalance Pro System and eBalance Home System. YoY comparisons indicate a material deterioration: net income is down 130.4% year-over-year and EPS down 600% over the same period. Management commentary (when available) would be critical to gauge path to profitability and capital strategy; however, the provided data does not include an earnings transcript to extract quotes or concrete forward-looking guidance.
On the balance sheet, CMXC exhibits extreme liquidity stress: cash and cash equivalents of $33,821 against total current liabilities of $665,274 and total liabilities of $1,021,051, resulting in an implausibly low current ratio of roughly 0.058. Negative stockholders’ equity (-$982,705) accompanies a debt load of $355,777, yielding a net debt position of approximately $321,956. Cash flow from operations was negative at -$16,519, further underscoring the need for external financing or a material reduction in burn. Given the absence of revenue data and the stark balance sheet, the near-term risk profile is dominated by liquidity and sustainability concerns rather than operating leverage.
In summary, the QQ2 2025 results portray a company at a crossroads: (1) potential upside from its diabetes/neuropathy device portfolio and remote/home-use systems, (2) but an immediate need to secure capital, reduce operating burn, and demonstrate revenue generation. The absence of earnings call transcripts in the provided data limits the ability to capture management’s qualitative outlook. Investors should closely monitor liquidity runway, any disclosed financing plans, milestones around product adoption, and potential partnerships that could unlock commercial value.
Key Performance Indicators
QoQ: -108.47% | YoY:-130.41%
QoQ: -337.50% | YoY:-600.00%
Key Insights
Revenue: Not disclosed for QQ2 2025; no QoQ/YoY revenue data available.
Net Income: -$139,508 for QQ2 2025; YoY change: -130.41% (negative). QoQ change: -108.47% (negative).
EPS: -$0.007 for QQ2 2025; YoY EPS change: -600.00%; QoQ EPS change: -337.50%.
Gross Profit / Gross Margin: Not disclosed.
Operating Income / Margin: Not disclosed.
EBITDA / Margin: Not disclosed.
Interest Expense: $8,810.
Total operating expenses: $79,924 (comprising General and Administrative of $57,424 and other op...
Financial Highlights
Revenue: Not disclosed for QQ2 2025; no QoQ/YoY revenue data available.
Net Income: -$139,508 for QQ2 2025; YoY change: -130.41% (negative). QoQ change: -108.47% (negative).
EPS: -$0.007 for QQ2 2025; YoY EPS change: -600.00%; QoQ EPS change: -337.50%.
Gross Profit / Gross Margin: Not disclosed.
Operating Income / Margin: Not disclosed.
EBITDA / Margin: Not disclosed.
Interest Expense: $8,810.
Total operating expenses: $79,924 (comprising General and Administrative of $57,424 and other operating costs).
Total other income/expenses net: -$139,508.
Income Before Tax: -$139,508.
Net Cash Flow from Operating Activities (CFO): -$16,519.
Free Cash Flow: -$16,519.
Cash and cash equivalents at period end: $33,821.
Balance Sheet Highlights: Total assets $38,346; total liabilities $1,021,051; total stockholders’ equity -$982,705; long-term debt $355,777; net debt approximately $321,956.
Liquidity indicators (from ratios): Current ratio 0.0576; Quick ratio 0.0576; Cash ratio 0.0508. These metrics imply severe liquidity constraints and a precarious balance sheet position.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Net Income |
-139.51K |
-130.41% |
-108.47% |
| EPS |
-0.01 |
-600.00% |
-337.50% |
Key Financial Ratios
operatingCashFlowPerShare
$-0
priceEarningsRatio
-15.09
Management Commentary
Earnings transcript not provided in the supplied data. As a result, no management quotes or themes from an earnings call are available to quote or contextualize in this report. If a transcript becomes available, we will extract themes under Strategy, Operations, and Market Conditions with direct quotes and context.
Forward Guidance
No explicit forward guidance is included in the provided data. Given the cash burn and limited visibility into revenue, a cautious view is warranted. Expected management focus areas should include: (1) securing additional capital or equity/debt facilities to extend runway, (2) advancing commercial adoption of the eBalance systems with clear revenue milestones, (3) cost containment and prioritization of high-potential clinical or professional-use deployments, and (4) partnerships/licensing arrangements to accelerate go-to-market. Our assessment suggests achievability of near-term improvements hinges on successful capitalization and credible revenue generation plans. Key factors investors should monitor: announced financing arrangements, milestones for regulatory/clinical progress, customer adoption metrics for eBalance Pro/Home, and any break-even path as device utilization scales.